A Hybrid Molecule Shows Promise for Obesity and Diabetes
A team at Helmholtz Munich has engineered a novel hybrid molecule that combines GLP-1/GIP signaling with a specific PPAR activator, offering a multi-target approach to treating obesity and type 2 diabetes.
A research team led by Prof. Timo D. Müller at Helmholtz Munich has developed a groundbreaking hybrid molecule designed to treat obesity and type 2 diabetes. The study, published in Nature, details a molecule that uses established GLP-1/GIP signaling as a delivery mechanism for a second metabolic modulator.
Targeting Five Drug Receptors at Once
- The hybrid molecule combines incretin components (GLP-1/GIP) with lanifibranor, a pan-PPAR agonist.
- It simultaneously targets five drug targets: GLP-1R, GIPR, and the three PPAR subtypes (α, γ, δ).
- The incretin portion binds to cell surface receptors, which facilitates the cellular uptake of the PPAR agonist.
- This targeted delivery allows for a lower dose of the PPAR agonist, potentially reducing systemic side effects.
Promising Results in Preclinical Models
In mouse studies using diet-induced obesity, the treatment yielded significant results compared to reference therapies.
- Mice ate less and lost more weight than those receiving a GLP-1/GIP co-agonist alone.
- Blood glucose levels improved, and insulin action appeared to be enhanced.
- Gastrointestinal side effects were comparable to existing incretin therapies.
- No indications of fluid retention or anemia were observed.
"Mice with diet-induced obesity ate less and lost more weight than those receiving a GLP-1/GIP co-agonist alone."
Key Limitations and Next Steps
The researchers are clear about the study's limitations and the work required before human application.
- This is a preclinical study; results may not translate to humans.
- The GIP receptor differs between mice and humans, requiring optimization for human use.
- The research team noted the need for industry partners for further development.